DescriptionSources: https://www.drugbank.ca/drugs/DB00093Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/felypressin.html | https://clinicaltrials.gov/ct2/show/NCT01073371 | https://www.mims.com/India/drug/info/prilocaine%20%2B%20felypressin/?type=full&mtype=generic#Indications | https://www.ncbi.nlm.nih.gov/pubmed/18655903 | https://www.ncbi.nlm.nih.gov/pubmed/3040881
Sources: https://www.drugbank.ca/drugs/DB00093
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/felypressin.html | https://clinicaltrials.gov/ct2/show/NCT01073371 | https://www.mims.com/India/drug/info/prilocaine%20%2B%20felypressin/?type=full&mtype=generic#Indications | https://www.ncbi.nlm.nih.gov/pubmed/18655903 | https://www.ncbi.nlm.nih.gov/pubmed/3040881
Felypressin is a non-catecholamine vasoconstrictor that is chemically related to vasopressin, the posterior pituitary hormone. Felypressin is added to some local anesthetics such as prilocaine in a concentration of 0.03 IU/ml. Its antidiuretic effects are less than those of vasopressin. Felypressin is used as a vasoconstrictor in local anesthetic injections for dental use and is an ingredient of preparations that have been used for the treatment of pain and inflammation of the mouth.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1889 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18655903 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16044058 |
Primary | Felypressin Approved UseUnknown |
Sample Use Guides
Adult: As combination containing prilocaine hydrochloride 30 mg and felypressin 0.03 IU/ml: Usual dose: 1-5 ml, adjust according to response. Max: 10 ml.
Child: As combination containing prilocaine hydrochloride 30 mg and felypressin 0.03 IU/ml: <10 yr: 1-2 ml; 10-18 yr: 1-5 ml, max 10ml. Adjust dose according to response.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3040881
Adenohypophyses, removed from decapitated rats, were divided into four segments of approximately equal size and incubated together for 150 min at 37 °C in 2-0 ml medium, ionically similar to cerebrospinal fluid containing ascorbic acid (1 mmol/1; pH 7-4), through which 95% O2 / 5% CO2 was passed continually. The medium was replaced after 120 and 135 min. The pituitary segments were then separated and incubated for a further 15 min, either in medium (1-0 ml) con¬ taining vasopressin-receptor agonist Felypressin and/or CRF-41 or in a corresponding volume of medium alone (controls). The medium was stored at
-30 °C and its ACTH concentration determined subsequently
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C80212
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07529MIG
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
4319
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB00093
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
D005259
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
1359
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
DTXSID6048599
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
m5258
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000091379
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
C81496
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
4910
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
17N2918V6G
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
200-282-7
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
56-59-7
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
14257662
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
60564
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908309
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY | |||
|
FELYPRESSIN
Created by
admin on Fri Dec 15 16:22:21 GMT 2023 , Edited by admin on Fri Dec 15 16:22:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY